Morningstar Founder Joe Mansueto: Decoding May Drip

Morningstar founder Joseph D. Mansueto sold an identical 7,250-share block on five separate trading days in early May 2026 — May 1, 4, 5, 6, and 7 — for aggregate disposition of 36,250 shares at prices ranging from $166.01 to $180.00 per share, generating roughly $6.1 million of cash proceeds. The constant 7,250-share daily lot size is the signature of a Rule 10b5-1 plan executing on a pre-set schedule, not a discretionary founder sale. More importantly, the disposition is microscopic relative to Mansueto's reported 37.5% beneficial-ownership stake in Morningstar.

The 13D/G tape resolves the ownership question with unusual clarity. SC 13G/A filings dated February 12, 2026 disclose two parallel Mansueto-family beneficial holdings: a 9.50% stake of 3,757,306 shares attributed to Daniel Mansueto and a 37.50% stake of 14,909,759 shares attributed to Joseph D. Mansueto. Those filings stay above the 5% reporting threshold and stay current — meaning the May 2026 Form 4 drip does not, as a matter of disclosed beneficial ownership, change the founder-control profile of the company.

What the daily lot size tells you

The mechanical view of Mansueto's early-May disposition cadence is uniform at the trading-day level. The aggregate Form 4 ticket data resolves to this view:

• May 1, 2026: 7,250 shares across 5 prints, $168.84-$174.21, residual ownership 8,143,342
• May 4, 2026: 7,250 shares across 4 prints, $168.56-$171.58, residual 8,133,986
• May 5, 2026: 7,250 shares across 4 prints, $167.12-$170.04, residual 8,124,790
• May 6, 2026: 7,250 shares across 4 prints, $166.01-$168.79, residual 8,115,765
• May 7, 2026: 7,250 shares across 12 prints, $166.66-$180.00, residual 8,114,392

The same constant share count appeared in Mansueto's February 2026 disposition window — 7,304 shares on February 17 and 6,737 shares on February 18 at prices in the $158-$163 range. Those numbers are close enough to indicate a plan that targets approximately 7,000-7,300 shares per scheduled trading day, with small variance reflecting partial-fill rounding rather than discretionary share-count choices.

Reading the ownership picture correctly

The single most common editorial mistake on a founder Form 4 sale is conflating the directly-disclosed Form 4 Table I share count with total beneficial ownership. Mansueto's Form 4 Table I residual after May 7 is 8,114,392 shares. That figure represents a portion of his disclosed beneficial holdings; the larger 14,909,759-share aggregate beneficial position reported in the February SC 13G/A captures family-trust and indirect-ownership entities that report through different filers.

Specifically: the SEC's beneficial-ownership rules under Section 13(d) aggregate shares over which the filer has voting or investment power, even if the underlying titles sit in trust or family-office vehicles. A Form 4 reports the filer's transaction; the SC 13G/A reports the filer's full beneficial position. Both numbers are true; they answer different questions. "Mansueto owns 8.1 million shares" is the Form 4 truth. "Mansueto controls 14.9 million shares (37.5%)" is the 13G truth. The 13G is the framing for thinking about influence over the company; the Form 4 is the framing for thinking about open-market disposition cadence.

The December 2025 gift

One other transaction in the recent record deserves a flag: on December 12, 2025, Mansueto reported a 27,775-share gift transaction (code G). Gift transactions are not market sales — they are dispositions to a recipient (typically a charitable trust or family member) and they do not affect float or supply-demand balance in the public market. The December gift dropped the Table I residual from approximately 8.6 million shares to 8.24 million shares without any cash proceeds to Mansueto. It is also the kind of transaction founder-controlled companies use at year-end for estate planning and donor-advised fund seeding.

The takeaway is that anyone reading the raw Form 4 stream needs to filter for transaction code — lumping gift transactions (G) into a "total sales" dollar number is a common but meaningless aggregation.

Why the timing isn't a tell

The Rule 10b5-1 safe harbor exists specifically to break the link between insider transactions and the insider's then-current view of the company. Mansueto's plan was almost certainly adopted in a prior open trading window — likely the post-Q4 2025 earnings window in late February or early March 2026 — and is now executing on autopilot.

For Morningstar specifically, the relevant catalysts that the plan was designed to operate around include:

• The Q1 2026 earnings release, scheduled for the late-April window (already past at the time of the May drip)
• The annual proxy and 14A filings, which formally disclose insider plan adoptions and refresh dates
• The next 13G/A annual amendment cycle, due February 2027, which will be the next chance to see whether the Mansueto-family aggregate beneficial position has materially shifted

None of those make the May plan execution a directional view on the stock. The plan is the plan.

The institutional read

The most concentrated institutional holders of MORN at the 2025Q4 13F cycle include the standard mandate-driven mega-passive complex (BlackRock, Vanguard Capital Management, State Street) plus a thinner active book that reflects Morningstar's relatively low free-float share count once the Mansueto-family stake is netted out. That free-float dynamic is what makes the 7,250-share daily disposition matter as a supply event — the daily lots are small in absolute terms, but they show up as a constant micro-bid drag on a name where structural supply is constrained by founder ownership.

What to watch through 2026

Three concrete anchors. First, the next Form 4 filing — if the 7,250-share daily pattern continues past mid-May, that confirms the plan is open-ended rather than capped at a fixed share total. Second, any new SC 13G/A filing from Mansueto or a Mansueto-family entity that materially changes the 37.5% beneficial-ownership disclosure — that would be the real founder-stake signal, not the daily plan drip. Third, the Morningstar 10-Q for Q1 2026, which will include footnote disclosure of any new 10b5-1 plan adoptions by named executive officers.

The headline framing of "founder sells $6M in stock" misses the point. The data says "plan executes 36,250 shares while the founder's 14.9M-share / 37.5% beneficial position stays intact." Those are very different stories.

See Mansueto's full Form 4 history →